AstraZeneca's NEPTUNE Fails, Xtandi Gets Priority Review, SENS Makes Sense

Today's Daily Dose brings you news about AstraZeneca's Imfinzi setback; Astellas Pharma's upcoming regulatory catalyst; Cresco Labs' better-than-expected revenue and real-world data of Senseonics' using Eversense CGM.

from RTT - Biotech https://ift.tt/31TpJP1
via IFTTT